Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157506 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02157506 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT02157506, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
Interventions
- DRUG Placebo
- DRUG CXL-1427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-06-30 |
| Est. Completion | 2015-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157506
The ClinicalTrials.gov registry entry for NCT02157506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02157506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157506 about?
NCT02157506 is a clinical study titled "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure". A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
What is the current status of trial NCT02157506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-06-30. Estimated completion is 2015-07-31.
What interventions are being tested in trial NCT02157506?
The interventions under investigation include: Placebo (DRUG), CXL-1427 (DRUG).
Who is sponsoring clinical trial NCT02157506?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.